subject area of
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer Academic Article
- Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review Academic Article
- Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women Academic Article
- CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned Academic Article
- Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer Academic Article
- Cognitive effects of aromatase inhibitor therapy in peripubertal boys Academic Article
- Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial Academic Article
- Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17 Academic Article
- Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17 Conference Paper
- Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17 Academic Article
- Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2– Advanced Breast Cancer Academic Article
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years Academic Article
- High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial Academic Article
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole Academic Article
- Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17 Academic Article
- Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen Academic Article
- New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole – Analyses from NCIC CTG MA.17 Academic Article
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05) Academic Article
- Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis Academic Article
- Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker Academic Article
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17 Academic Article
- Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial Academic Article
- Reduction in Endometrioma Size with Three Months of Aromatase Inhibition and Progestin Add-Back Academic Article
- The extended adjuvant NCIC CTG MA.17 trials: Initial and rerandomization studies Academic Article
- Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria? Academic Article
- Use of letrozole challenge test to adjust gonadotropin dose in non–down-regulated cycles Academic Article